Phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in small cell cancer of the lung.
Nineteen patients with a histologically confirmed diagnosis of small cell carcinoma (SCCL) of the lung were entered on trial with a new nitrosourea, 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU). All patients had had prior chemotherapy and 42% had received a nitrosourea. No patient had a major response to treatment with PCNU and only one patient had a minor response of short duration. Myelosuppression, particularly thrombocytopenia, was the major dose-limiting side effect. PCNU did not appear to be of benefit in patients with recurrent SCCL.